To increase appropriate use of long-acting injectables (LAI), this 12-week virtual learning collaborative will focus on increasing use of LAIs to serve the needs of patients with serious mental illness. LAIs are associated with decreased risks of relapse, improvements in symptoms, functioning, and patient satisfaction.
This collaborative is intended for clinicians who want to optimize LAI use for their patients. Through the 12-week activity, participants will increase access to LAIs using the following steps: improving knowledge about the various formulations of LAIs, their pharmacokinetics and pharmacodynamics, considering patient eligibility for LAIs, developing an effective strategy for having a conversation about LAIs, monitoring for side effects of LAIs and manage them if they occur, and successfully treating breakthrough symptoms for people taking LAIs.
By the end of the learning collaborative, participants will increase their knowledge about LAIs, and may more effectively discuss with their patients the risks and benefits of these medications.